Literature DB >> 11394884

Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication.

M Wada1, N A Wada, H Shirono, K Taniguchi, H Tsuchie, J Koga.   

Abstract

CD8+ T lymphocytes have been shown to produce unidentified soluble factors active in suppressing HIV-1 replication. In this study, we purified an HIV-1 suppressing activity from the culture supernatant of an immortalized CD8+ T cell clone, derived from an HIV-1 infected long-term nonprogressor, and identified this activity as the amino-terminal fragment (ATF) of urokinase-type plasminogen activator (uPA). ATF is catalytically inactive, but suppresses the release of viral particles from the HIV-1 infected cell lines via binding to its receptor CD87. In contrast, cell proliferation and the secretion of an HIV-1 LTR driven reporter gene product were not affected by ATF. These findings suggest that ATF may inhibit the assembly and budding of HIV-1, which provides a novel therapeutic strategy for AIDS. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11394884     DOI: 10.1006/bbrc.2001.4965

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages.

Authors:  Arevik Mosoian; Avelino Teixeira; Anthony A High; Robert E Christian; Donald F Hunt; Jeffrey Shabanowitz; Xinyan Liu; Mary Klotman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza.

Authors:  Baoquan Sui; Douty Bamba; Ke Weng; Huong Ung; Shaojing Chang; Jessica Van Dyke; Michael Goldblatt; Roxanne Duan; Michael S Kinch; Wu-Bo Li
Journal:  Virology       Date:  2009-03-27       Impact factor: 3.616

Review 3.  Host hindrance to HIV-1 replication in monocytes and macrophages.

Authors:  Anna Bergamaschi; Gianfranco Pancino
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

4.  Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Authors:  Massimo Alfano; Samanta A Mariani; Chiara Elia; Ruggero Pardi; Francesco Blasi; Guido Poli
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

5.  Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication.

Authors:  Massimo Alfano; Nicolai Sidenius; Barbara Panzeri; Francesco Blasi; Guido Poli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

6.  Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases.

Authors:  Manuela Nebuloni; Paola Cinque; Nicolai Sidenius; Angelita Ferri; Eleonora Lauri; Elisabetta Omodeo-Zorini; Pietro Zerbi; Luca Vago
Journal:  J Neurovirol       Date:  2008-12-24       Impact factor: 2.643

7.  Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCε.

Authors:  Francesca Graziano; Chiara Elia; Carlo Laudanna; Guido Poli; Massimo Alfano
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

8.  The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.

Authors:  Uffe V Schneider; Rikke L Nielsen; Court Pedersen; Jesper Eugen-Olsen
Journal:  BMC Infect Dis       Date:  2007-11-16       Impact factor: 3.090

9.  HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression.

Authors:  Manuela Nebuloni; Lidia Zawada; Angelita Ferri; Antonella Tosoni; Pietro Zerbi; Massimo Resnati; Guido Poli; Luca Genovese; Massimo Alfano
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.